Kim Young-Tak, Serrano Beatriz, Lee Jae-Kwan, Lee Hyunju, Lee Shin-Wha, Freeman Crystal, Oh Jin-Kyoung, Alemany Laia, Bosch Francesc-Xavier, Bruni Laia
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Català d'Oncologia (ICO) - Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigacion Biomédica en Red de Cancer (CIBERONC), Madrid, Spain.
Papillomavirus Res. 2019 Jun;7:26-42. doi: 10.1016/j.pvr.2018.12.002. Epub 2018 Dec 30.
We aimed to review the burden and the potential impact of human papillomavirus (HPV) vaccines on HPV-related diseases in the Republic of Korea and to discuss cervical cancer prevention practices in this country.
Cancer burden statistics were retrieved from GLOBOCAN-2018 and Statistics Korea. HPV disease burden was assessed via systematic review. Vaccine types relative contribution (RC) was estimated using data from an international project using formalin-fixed paraffin-embedded specimens.
Despite a downtrend in cervical cancer in recent years, Korean rates remain high. In contrast, oropharyngeal cancer incidence has gradually increased and other anogenital cancers remain rare. In Korea, HPV prevalence in general population is around 20%. In cervical cancer, RC of HPVs 16/18 (74.0%) increased to 92.0% when including HPVs 31/33/45/52/58. Limited information was available for other HPV-related cancer sites. Regarding prevention, since the inclusion of the HPV vaccine into the National Immunization Program, almost half (49%) of the target cohort in 2016 had received the first dose of vaccine. Further, percentage of women screened with pap has increased from 41.1%-2009 to 53.0%-2016.
HPV-related disease burden in Korea is significant. Results suggest that the combination of effective and high coverage HPV vaccination and screening programmes could substantially impact on HPV-related disease in Korea.
我们旨在回顾韩国人乳头瘤病毒（HPV）疫苗对HPV相关疾病的负担及潜在影响，并讨论该国的宫颈癌预防措施。
从全球癌症负担数据库（GLOBOCAN-2018）和韩国统计局获取癌症负担统计数据。通过系统评价评估HPV疾病负担。使用来自一个国际项目的数据，该项目采用福尔马林固定石蜡包埋标本，估计疫苗类型的相对贡献（RC）。
尽管近年来宫颈癌发病率呈下降趋势，但韩国的发病率仍然很高。相比之下，口咽癌发病率逐渐上升，其他肛门生殖器癌症仍然罕见。在韩国，普通人群中的HPV流行率约为20%。在宫颈癌中，HPV 16/18型的相对贡献（RC）（74.0%）在纳入HPV 31/33/45/52/58型时增加到92.0%。关于其他HPV相关癌症部位的信息有限。在预防方面，自HPV疫苗纳入国家免疫规划以来，2016年几乎一半（49%）的目标队列接种了第一剂疫苗。此外，接受巴氏涂片筛查的女性比例从2009年的41.1%增加到了2016年的53.0%。
韩国HPV相关疾病负担较重。结果表明，有效的高覆盖率HPV疫苗接种和筛查计划相结合，可能会对韩国的HPV相关疾病产生重大影响。
